New Drug SCYX-7158 for Treating Sleeping Sickness
Author Information
Author(s): Jacobs Robert T., Nare Bakela, Wring Stephen A., Orr Matthew D., Chen Daitao, Sligar Jessica M., Jenks Matthew X., Noe Robert A., Bowling Tana S., Mercer Luke T., Rewerts Cindy, Gaukel Eric, Owens Jennifer, Parham Robin, Randolph Ryan, Beaudet Beth, Bacchi Cyrus J., Yarlett Nigel, Plattner Jacob J., Freund Yvonne, Ding Charles, Akama Tsutomu, Zhang Y.-K., Brun Reto, Kaiser Marcel, Scandale Ivan, Don Robert
Primary Institution: SCYNEXIS, Inc.
Hypothesis
SCYX-7158 is an effective, safe, and orally active treatment for stage 2 Human African Trypanosomiasis.
Conclusion
SCYX-7158 shows promise as an effective and safe treatment for stage 2 HAT and is set to enter preclinical studies.
Supporting Evidence
- SCYX-7158 was effective in both stage 1 and stage 2 murine HAT models.
- The compound demonstrated high bioavailability and good CNS penetration.
- In vivo studies showed a 100% cure rate in mice at doses as low as 5 mg/kg.
Takeaway
Scientists found a new medicine called SCYX-7158 that can help treat a serious disease called sleeping sickness, which affects the brain.
Methodology
The study involved drug discovery through biological screening, medicinal chemistry, and pharmacokinetic characterization in murine models.
Limitations
The study primarily involved animal models, and further clinical trials are needed to confirm efficacy in humans.
Participant Demographics
The study involved female Swiss Webster mice.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website